<DOC>
	<DOCNO>NCT00002869</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Low dos interferon alfa may effective high dos . PURPOSE : Randomized phase III trial compare effectiveness low-dose high-dose interferon alfa treat patient newly diagnose chronic myelogenous leukemia .</brief_summary>
	<brief_title>Interferon Alfa Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare duration chronic phase survival follow low- vs. high-dose interferon alfa maintenance therapy patient chronic myelogenous leukemia chronic phase . II . Compare toxicity profile , assess WHO criteria , percentage patient require dose reduction discontinuation two regimen . III . Compare hematologic cytogenetic response every 6 month patient treat two regimen . OUTLINE : This randomize study . Patients receive daily hydroxyurea white blood cell count ( WBC ) maintain normal level 2-3 week . Patients randomize two group : one group receive daily high-dose interferon alfa , receive low-dose interferon alfa , 5 day per week . Both group continue receive hydroxyurea reduce dos need maintain normal WBC . Treatment continue disease progression occurs . Patients may receive cytarabine addition interferon either treatment arm investigator 's discretion . Cytarabine give subcutaneously 10 day every calendar month continue absence disease progression unacceptable toxicity . Patients follow every 6 month survival . PROJECTED ACCRUAL : Approximately 800 patient enrol 8 year multicenter study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chronic myelogenous leukemia chronic phase Molecular evidence BCR/ABL rearrangement OR Presence Philadelphia chromosome Eligibility allogeneic bone marrow transplantation exclude PATIENT CHARACTERISTICS : Age : Adult Performance status : WHO 02 Hematopoietic : Not specify Hepatic : Bilirubin le twice normal No severe hepatic problem Renal : Creatinine le twice normal No severe renal problem Cardiovascular : No severe cardiovascular problem Other : No contraindication interferon therapy No history severe depression No pregnant woman Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : No prior therapy Prior therapeutic backup leukapheresis allow Hydroxyurea may start 4 week prior entry</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
</DOC>